Conolidine’s analgesic outcomes stem from its conversation with non-opioid pain pathways. As opposed to opioids, which bind to µ-opioid receptors from the central anxious process, conolidine modulates alternate molecular targets. A Science Advances research discovered that conolidine interacts With all the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide https://johnr098wad1.wizzardsblog.com/profile